Literature DB >> 6985269

Inhibition of in vitro natural killer activity by the third component of complement: role for the C3a fragment.

C Charriaut, A Senik, J P Kolb, M Barel, R Frade.   

Abstract

Purified human native third component of complement, C3, was found to inhibit in vitro natural killer (NK) cell cytotoxicity in both mouse and human systems. The effect was dose and time dependent, a 50% inhibition being reached with 190 nM C3 (35 micrograms/ml) added during the NK assay or after a 30-min preincubation of the effector cells with this C3 concentration. C3 was shown to act at the effector-cell population level because pretreatment of the target cells did not modify the NK lysis. The inhibition was not due to general cytotoxicity nor to cell agglutination. Moreover, another in vitro cytotoxicity system (represented by alloreactive cytotoxic lymphocytes) was not affected by purified C3. Structural analysis of the active part of the C3 molecule shows that the C3-induced inhibition is supported by the C3a fragment. Release of carboxyl-terminal arginine residue by carboxypeptidase B, converting C3a into des-Arg77-C3a, did not alter the inhibitory effect displayed by this fragment. These results suggest that C3a may play an important role in the regulation of NK activity.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6985269      PMCID: PMC347040          DOI: 10.1073/pnas.79.19.6003

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  22 in total

Review 1.  An analysis of the murine NK cell as to structure, function and biological relevance.

Authors:  R Kiessling; H Wigzell
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

2.  A rapid method for the isolation of functional thymus-derived murine lymphocytes.

Authors:  M H Julius; E Simpson; L A Herzenberg
Journal:  Eur J Immunol       Date:  1973-10       Impact factor: 5.532

3.  Sites of production of primate serum proteins associated with complement system.

Authors:  V J Stecher; J H Morse; G J Thorbecke
Journal:  Proc Soc Exp Biol Med       Date:  1967-02

4.  Murine NK cell cultures: effects of interleukin-2 and interferon on cell growth and cytotoxic reactivity.

Authors:  K Kuribayashi; S Gillis; D E Kern; C S Henney
Journal:  J Immunol       Date:  1981-06       Impact factor: 5.422

5.  Isolation and characterization of a C3b receptor-like molecule from membranes of a human B lymphoblastoid cell line (Raji).

Authors:  M Barel; C Charriaut; R Frade
Journal:  FEBS Lett       Date:  1981-12-21       Impact factor: 4.124

6.  Isolation of human NK cells by density gradient centrifugation.

Authors:  T Timonen; E Saksela
Journal:  J Immunol Methods       Date:  1980       Impact factor: 2.303

7.  Inhibition of secondary in vitro antibody responses by the third component of complement.

Authors:  M V Hobbs; T L Feldbush; B W Needleman; J M Weiler
Journal:  J Immunol       Date:  1982-03       Impact factor: 5.422

8.  Membrane distribution and adsorptive endocytosis by C3b receptors on human polymorphonuclear leukocytes.

Authors:  D T Fearon; I Kaneko; G G Thomson
Journal:  J Exp Med       Date:  1981-06-01       Impact factor: 14.307

9.  Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum.

Authors:  V A Bokisch; H J Müller-Eberhard; C G Cochrane
Journal:  J Exp Med       Date:  1969-05-01       Impact factor: 14.307

10.  Anaphylatoxin-mediated regulation of the immune response. I. C3a-mediated suppression of human and murine humoral immune responses.

Authors:  E L Morgan; W O Weigle; T E Hugli
Journal:  J Exp Med       Date:  1982-05-01       Impact factor: 14.307

View more
  7 in total

1.  Complement regulates conventional DC-mediated NK-cell activation by inducing TGF-β1 in Gr-1+ myeloid cells.

Authors:  Xiaoping Qing; Gloria C Koo; Jane E Salmon
Journal:  Eur J Immunol       Date:  2012-06-05       Impact factor: 5.532

Review 2.  Rituximab: mechanism of action.

Authors:  George J Weiner
Journal:  Semin Hematol       Date:  2010-04       Impact factor: 3.851

3.  The Combination of Radiotherapy and Complement C3a Inhibition Potentiates Natural Killer cell Functions Against Pancreatic Cancer.

Authors:  Quaovi H Sodji; Dhanya K Nambiar; Vignesh Viswanathan; Rie von Eyben; Deana Colburg; Michael S Binkley; Caiyun G Li; Monica M Olcina; Daniel T Chang; Quynh-Thu Le; Amato J Giaccia
Journal:  Cancer Res Commun       Date:  2022-07-27

4.  Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity.

Authors:  C Scheid; R Young; R McDermott; L Fitzsimmons; J H Scarffe; P L Stern
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

5.  Human natural killer cells, activated lymphocyte killer cells, and monocytes possess similar cytotoxic mechanisms.

Authors:  G F Burns; T Triglia; P F Bartlett; I R Mackay
Journal:  Proc Natl Acad Sci U S A       Date:  1983-12       Impact factor: 11.205

6.  Recombinant acylation stimulating protein administration to C3-/- mice increases insulin resistance via adipocyte inflammatory mechanisms.

Authors:  Mercedes Nancy Munkonda; Marc Lapointe; Pierre Miegueu; Christian Roy; Danny Gauvreau; Denis Richard; Katherine Cianflone
Journal:  PLoS One       Date:  2012-10-08       Impact factor: 3.240

7.  Human platelet activation by C3a and C3a des-arg.

Authors:  M J Polley; R L Nachman
Journal:  J Exp Med       Date:  1983-08-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.